| The genomic landscape of endocrine-resistant advanced breast cancers P Razavi, MT Chang, G Xu, C Bandlamudi, DS Ross, N Vasan, Y Cai, ... Cancer cell 34 (3), 427-438. e6, 2018 | 672 | 2018 |
| Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade W Abida, ML Cheng, J Armenia, S Middha, KA Autio, HA Vargas, ... JAMA oncology 5 (4), 471-478, 2019 | 456 | 2019 |
| Tumour lineage shapes BRCA-mediated phenotypes P Jonsson, C Bandlamudi, ML Cheng, P Srinivasan, SS Chavan, ... Nature 571 (7766), 576-579, 2019 | 289 | 2019 |
| Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions ML Cheng, E Pectasides, GJ Hanna, HA Parsons, AD Choudhury, ... CA: A Cancer Journal for Clinicians, 2020 | 102 | 2020 |
| Impact of DNA damage response and repair (DDR) gene mutations on efficacy of PD-(L) 1 immune checkpoint inhibition in non-small cell lung cancer B Ricciuti, G Recondo, LF Spurr, YY Li, G Lamberti, D Venkatraman, ... Clinical Cancer Research, 2020 | 91 | 2020 |
| Effects of RANKL-targeted therapy in immunity and cancer ML Cheng, L Fong Frontiers in oncology 3, 329, 2014 | 84 | 2014 |
| The incidence of oesophageal cancer in Eastern Africa: identification of a new geographic hot spot? ML Cheng, L Zhang, M Borok, E Chokunonga, C Dzamamala, A Korir, ... Cancer epidemiology 39 (2), 143-149, 2015 | 71 | 2015 |
| Abiraterone acetate for the treatment of prostate cancer CJ Ryan, ML Cheng Expert opinion on pharmacotherapy 14 (1), 91-96, 2013 | 34 | 2013 |
| Clinical tumour sequencing for precision oncology: time for a universal strategy ML Cheng, MF Berger, DM Hyman, DB Solit Nature Reviews Cancer 18 (9), 527-528, 2018 | 33 | 2018 |
| Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas JM Sands, T Nguyen, P Shivdasani, AG Sacher, ML Cheng, RS Alden, ... Lung Cancer 140, 35-41, 2020 | 23 | 2020 |
| Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab MA Postow, SD Chasalow, D Kuk, KS Panageas, ML Cheng, J Yuan, ... Melanoma Research 30 (1), 71-75, 2020 | 23 | 2020 |
| Does TMB impact the effectiveness of TKIs in EGFR-mutant NSCLC? ML Cheng, GR Oxnard Clinical Cancer Research 25 (3), 899-900, 2019 | 19 | 2019 |
| Beyond sipuleucel-T: immune approaches to treating prostate cancer ML Cheng, L Fong Current treatment options in oncology 15 (1), 115-126, 2014 | 18 | 2014 |
| Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC ML Cheng, CJ Lau, MSD Milan, JG Supplee, JW Riess, PA Bradbury, ... JCO Precision Oncology 5, 393-402, 2021 | 16 | 2021 |
| Microsatellite instability in prostate cancer and response to immune checkpoint blockade. W Abida, ML Cheng, J Armenia, S Middha, KA Autio, DE Rathkopf, ... Journal of Clinical Oncology 36 (15_suppl), 5020-5020, 2018 | 16 | 2018 |
| Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs ML Cheng, MTA Donoghue, F Audenet, NC Wong, EJ Pietzak, CM Bielski, ... JCO Precision Oncology 4, 1307-1320, 2020 | 13 | 2020 |
| Turnaround Time of Plasma Next-Generation Sequencing in Thoracic Oncology Patients: A Quality Improvement Analysis Y Lee, EW Clark, MSD Milan, C Champagne, KS Michael, MM Awad, ... JCO Precision Oncology 4, 1098-1108, 2020 | 12 | 2020 |
| Coccidioidal endophthalmitis in immunocompetent Person, California, USA ML Cheng, M Leibowitz, E Ha Emerging infectious diseases 18 (6), 1015, 2012 | 10 | 2012 |
| Novel biomarkers in bladder cancer ML Cheng, G Iyer Urologic Oncology: Seminars and Original Investigations 36 (3), 115-119, 2018 | 7 | 2018 |
| Opportunities and challenges in genomic sequencing for precision cancer care ML Cheng, DB Solit Annals of internal medicine 168 (3), 221-222, 2018 | 6 | 2018 |
